Ipamorelin is a synthetic pentapeptide belonging to the Growth Hormone Releasing Peptide (GHRP) class — compounds that stimulate HGH secretion through a receptor pathway distinct from GHRH. What distinguishes Ipamorelin within this class is its selectivity profile: it stimulates HGH release with minimal effect on other pituitary hormones like cortisol and prolactin that earlier GHRPs co-stimulated. This selectivity has made it a valuable research tool for studying selective GH axis activation.
The Ghrelin Receptor: How Ipamorelin Works
GHRPs including Ipamorelin do not act through the GHRH receptor. They act through the growth hormone secretagogue receptor (GHSR), which is also known as the ghrelin receptor — named after ghrelin, the endogenous ligand that was discovered after the synthetic GHRPs that targeted this receptor.
The GHSR is expressed in the pituitary (on somatotrophs) and in the hypothalamus (on neurons that modulate GHRH and somatostatin release). Ghrelin receptor activation in the pituitary directly stimulates HGH release; activation in the hypothalamus increases GHRH release and reduces somatostatin tone, amplifying pituitary responsiveness.
This dual mechanism — direct pituitary stimulation plus hypothalamic priming — means GHRPs and GHRH analogues can have synergistic effects when used together in research, as they act at complementary points in the HGH secretion pathway.
| Item | Detail |
| Receptor target | GHSR (ghrelin receptor) — distinct from GHRH receptor |
| Pituitary action | Direct somatotroph stimulation → HGH release |
| Hypothalamic action | Increases GHRH output, reduces somatostatin tone |
| Selectivity | HGH > cortisol, prolactin (selective vs earlier GHRPs) |
| Molecular weight | ~711 Da |
| CAS Number | 170851-70-4 |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 (pentapeptide) |
Selectivity: What Makes Ipamorelin Different From Earlier GHRPs
The GHRP class includes several compounds developed over time: GHRP-6, GHRP-2, Hexarelin, and Ipamorelin, among others. Earlier compounds in this class — particularly GHRP-6 and Hexarelin — produced significant co-stimulation of cortisol and prolactin release in research models alongside their HGH-stimulating effects. This was a significant limitation for research applications where clean GH axis stimulation was desired without confounding hormonal changes.
Ipamorelin was developed with selectivity as a design goal. Research comparing the hormonal response profiles of different GHRPs has consistently documented that Ipamorelin produces HGH increases with markedly less cortisol and prolactin elevation than GHRP-6 or Hexarelin at equivalent HGH-stimulating doses. GHRP-2 sits between Ipamorelin and the older compounds in selectivity.
The molecular basis for this selectivity involves subtle structural differences in how different GHRPs interact with the GHSR, leading to different patterns of receptor signalling and downstream effects on pituitary cells beyond somatotrophs.
Ipamorelin and the Pulsatile HGH Pattern
Like CJC-1295 and unlike exogenous HGH, Ipamorelin stimulates HGH release within the context of the body’s normal pulsatile secretion pattern. Administration produces an acute HGH pulse lasting 2-3 hours in research models, rather than suppressing natural rhythms. This is consistent with Ipamorelin acting as a stimulus for normal pituitary function rather than replacing it.
Research examining the combination of Ipamorelin with GHRH analogues like CJC-1295 has reported synergistic HGH responses — larger pulses than either compound alone would produce. This synergy makes mechanistic sense given their complementary mechanisms: Ipamorelin primes the pituitary via the ghrelin receptor while CJC-1295 stimulates via the GHRH receptor, with both signals converging on somatotroph activation.
Somatostatin Interaction Research
One of the research advantages of Ipamorelin is its ability to stimulate HGH release even when somatostatin tone is relatively high — a property that distinguishes it from pure GHRH analogues, which are strongly inhibited by somatostatin. Research has shown that ghrelin receptor activation can partially overcome somatostatin inhibition, effectively lowering the threshold for HGH secretion.
This property has made Ipamorelin useful in research models examining GH secretion in conditions of elevated somatostatin tone — such as aged animal models where somatostatin activity is increased as part of the somatopause mechanism. Studies have reported that Ipamorelin can restore significant HGH pulse amplitude in aged rodents where GHRH-only stimulation is less effective.
Ipamorelin’s selectivity for HGH over cortisol and prolactin makes it a significantly cleaner research tool than earlier GHRPs when studying isolated GH axis effects. Its ghrelin receptor mechanism and complementarity with GHRH analogues make it a foundational compound in GH secretagogue research.